CTI Biopharma Corp expected to post a loss of 41  cents a share - Earnings Preview

CTI Biopharma

11/05/2022 24:21

* CTI Biopharma Corp  CTIC.OQ   CTIC.O  is expected to show
a rise
in quarterly revenue when it reports  results on May 12. 
    * The Seattle Washington-based  company is expected to
report
revenue of $1.54 million, according to the mean estimate from 5
analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for CTI Biopharma Corp
is for
a loss of 41 cents per share. For the same quarter last year,
the company reported a loss of 23 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 7.1%
in the last three months. ​
    * Wall Street's median 12-month price target for CTI
Biopharma
Corp is $9​, above​ its last closing price of $3.95. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.28       -0.28      -0.38     Missed  -34.9
 Sep. 30 2021  -0.22       -0.25      -0.26     Missed  -4.7
 Jun. 30 2021  -0.21       -0.21      -0.21     Met     0​
 Mar. 31 2021  -0.22       -0.22      -0.23     Missed  -5.7
 ​​Dec.                    -0.16      -0.20     Missed  -27
 31 2020                                                
 Sep. 30 2020  -0.15       -0.15      -0.15     Met     2.2​
 Jun. 30 2020  -0.12       -0.12      -0.14     Missed  -13.5
 Mar. 31 2020  -0.13       -0.13      -0.20     Missed  -53.8
 This summary was machine generated May 10 at 23:21 GMT.  All
figures in US dollars  unless otherwise stated